Diaceutics PLC · LSE:DXRX
Diaceutics — Investor Presentation (June 2024)
19 slides from Diaceutics's investor presentation, June 2024
Slide 1: Helping pharma find patients
Helping pharma find patients Corporate Overview – May / June 2024 Ryan Keeling | Chief Executive Officer | [email protected] Nick Roberts | Chief Financial Officer | [email protected] 1 © copy right Diaceutics 2024 Permission must be sought f rom Diaceutics if y ou wish to reprod
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements Disclaimer : The information provided in this presentation is for the sole use of those attending the presentation This presentation has been prepared by Diaceutics the (“Company”). “Pre sentation” means this document, any oral presentation, any question and
Slide 3: We help pharma find patients: 3 unique assets
We help pharma find patients: 3 unique assets 1. Lab network 2. Data 3. DXRX Platform Global network of World’s largest World’s first diagnostic 900 + labs repository of commercialisation platform for healthcare data precision medicine Pharma Labs Physicians Patients • ID patients daily • ↑ Diagnost
Slide 4: What is precision medicine?
What is precision medicine? Precision Medicine (PM) is the tailoring of medical treatment to the individual characteristics of each patient – a patient’s unique genetic profile makes them susceptible to certain diseases and can influence which treatments will be safe and effective for them PM is res
Slide 5: The diagnostic challenge: Precision medicine practice gaps
The diagnostic challenge: Precision medicine practice gaps The healthcare Physicians ‘Practice Gaps’ Pharma are Our diagnostic eco-system can’t link are materially losing out on commercialization hasn’t caught patients to the impacting patient potential platform – DXRX – up with right drug. quality
Slide 6: 19 Years of performance & growth
19 Years of performance & growth 2005-2010 2011-2015 2016-2019 2020-2023 • Co-founded by • 1st implementation • Exporter of the Year • Launch DXRX - The Diagnostic Peter & Ryan service Network® • Introduced AI Keeling • Lab service network • IPO on AIM • New Diaceutics HQ • Diaceutics • Launched PM
Slide 7: Diaceutics - Today and the future
Diaceutics - Today and the future 184 69 people therapeutic brands 2024 + • Capture significant & growing market opportunity 13 6 • Continue to scale rapidly & profitably countries enterprise-wide engagements • Enterprise-wide engagements to drive momentum • Focus on recurring revenue • Deploy enhan
Slide 8: Significant & growing market opportunity
Helping pharma Significant & growing market opportunity find patients Global pharma rapidly shifting to precision medicine to find more patients, capture lost revenue and increase profitability Growth driven by customer success Strong competitive Compelling Financial Demonstrable track advantage val
Slide 9: The DXRX solution
The DXRX solution Insights & Engagement Scientific & Advisory Solutions Services Real-world patient data products & digital Scientific solutions & consulting engagement solutions: services: • Signal • Strategy & Planning • Education & Content • Lab & Physician Segmentation • Impact Assessments • Lab
Slide 10: Our IP - DXRX transforming data into insights
Our IP - DXRX transforming data into insights Diaceutics Diagnostic Product Data Deductive Insights Pathways Insights Solutions Expert Engagement Solutions (DDPs) Insight Patient histories AI / ML Solutions labelling Multiple (Data) Testing/ diseases treatment Lab Raw data Stage of Results/ Segmenta
Slide 11: What we do - A DXRX Signal case study
What we do - A DXRX Signal case study 500+ US labs supplying weekly Patient lead generation 2023 The challenge data Week 2 Week 4 Due to the rarity of certain Week 6 biomarkers, the identification of Week 8 eligible patients is challenging. Week 1 0 Week 1 2 It was critical for the client to Week 1
Slide 12: DXRX Signal - Patient intervention points
DXRX Signal - Patient intervention points 12 © copy right Diaceutics 2024 Permission must be sought f rom Diaceutics if y ou wish to reproduce any part of this presentation Permission must be sought from Diaceutics if you w ish to reproduce any part of this presentation
Slide 13: Industry leaders in diagnostic commercialisation
Industry leaders in diagnostic commercialisation PETER KEELING DAVID BROWN AMIE McNIECE Co-Founder VP Operations VP Marketing RYAN KEELING SARAH BONDI KENNETH RUPPEL Chief Executive Officer & VP Data Partnerships & Strategy VP Scientific & Medical Services Co-Founder NICK ROBERTS SCOTT GAMESTER MARI
Slide 14: Strategy update
Strategy update Enrich data & Accelerate growth Invest in Transform our platform products & engagement of platform scale customer lab network & capability experience & service • Daily Signal launched • Laboratory network • Investment in • Listening to our • Tokenisation of data and platform- innovat
Slide 15: Financial strength
Financial strength Ability to deliver exceptionally high margins through operational leverage Revenue CAGR of 23% over past 3 years 52% of revenues are now recurring in nature and growing – good order book visibility Enterprise-wide engagements with blue-chip customers will drive momentum Strong bal
Slide 16: Financial dashboard
Financial dashboard Revenue Recurring revenue Order book value Cash & equivalents £23.7m 52% £26.5m £16.7m Up 22% ARR of £13.7m of 57% growth In line with which £9.0m relates YoY investment plans 19% constant currency to enterprise growth engagements from £19.5m from 35% from £16.9m from £19.8m in F
Slide 17: Operational dashboard
Operational dashboard 6 enterprise-wide 7 dedicated 69 customer 37 therapies with engagements customer account therapeutic lifetime revenues ARR of £9.0m teams brands over $1 million Up from four 184 employees Up 23% from Up from 26 in FY 2023 151 - FY 2022 56 in FY 2022 AI upgrades to 941 labs on n
Slide 18: Outlook & future growth
Outlook & future growth • Capture significant & growing market opportunity • Continue to scale rapidly & profitably • Enterprise-wide engagements to drive momentum • Focus on recurring revenue • Deploy enhanced technologies across DXRX platform • Grow beyond pharma - biotech, life science & payers A
Slide 19: Team & contacts
Team & contacts Ryan Keeling Nick Roberts Chief Executive Officer Chief Financial Officer [email protected] Christian Glennie | Stifel | [email protected] Hayley Palmer | Canaccord Genuity | [email protected] Julie Simmonds | Panmure Gordon | [email protected] Natali